Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MJardin Group, Inc. (MJARF)
Toronto, ON, CA
MJardin Group Inc. is a company actively involved in the cultivation, harvesting, processing, and sale of cannabis products throughout Canada and the United States. Beyond its own product lines, MJardin extends its expertise by offering a comprehensive suite of consulting and advisory services to other licensed cannabis operators, specifically those engaged in cultivation and retail. This support covers a broad spectrum, including strategic capital and financing, project management for cultivation facilities, assistance with licensure, facility design, system implementation, property and equipment leasing, construction oversight, and the critical operational ramp-up phase. The company also provides access to its proprietary intellectual property. MJardin's influence spans a portfolio of 32 cannabis operations, which it either owns, manages, or provides guidance for. Established in 2014, the company maintains its headquarters in Ontario, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +900.00% | -99.81% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-57.2% Q3'21: -72.5% (vs Q3'20)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+89.6% ★ Q3'21: -375.0% (vs Q3'20)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-220.2% Q3'21: -164.5% (vs Q3'20)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-26.5% Q3'21: -1,235.8% (vs Q3'20)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-4.1% Q3'21: -113.1% (vs Q3'20)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+8.7% Q3'21: +6.0% (vs Q3'20)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-100.71× Q3'21: -2.79× (vs Q3'20)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
27.51M
est: 33.80M (-18.6%)
|
26.70M
est: 35.03M (-23.8%)
|
11.44M
est: 15.33M (-25.4%)
|
36.58M
est.
|
38.45M
est.
|
36.69M
est.
|
37.29M
37.29M – 37.29M
+1.6% YoY
|
36.67M
36.67M – 36.67M
-1.7% YoY
|
16.75M
16.75M – 16.75M
-54.3% YoY
|
40.02M
40.02M – 40.02M
+139.0% YoY
|
| EBITDA |
-59.48M
est: -20.68M (-187.7%)
|
-248.24M
est: -21.43M (-1,058.2%)
|
-1.64M
est: -9.38M (+82.5%)
|
-22.38M
est.
|
-23.53M
est.
|
-22.45M
est.
|
-22.82M
-22.82M – -22.82M
-1.6% YoY
|
-22.44M
-22.44M – -22.44M
+1.7% YoY
|
-10.25M
-10.25M – -10.25M
+54.3% YoY
|
-24.49M
-24.49M – -24.49M
-139.0% YoY
|
| EBIT |
-60.15M
est: -21.52M (-179.5%)
|
-249.71M
est: -22.31M (-1,019.4%)
|
-3.03M
est: -9.77M (+68.9%)
|
-23.29M
est.
|
-24.49M
est.
|
-23.36M
est.
|
-23.75M
-23.75M – -23.75M
-1.6% YoY
|
-23.35M
-23.35M – -23.35M
+1.7% YoY
|
-10.67M
-10.67M – -10.67M
+54.3% YoY
|
-25.49M
-25.49M – -25.49M
-139.0% YoY
|
| Net Income |
-84.25M
est: -7.72M (-990.8%)
|
-267.47M
est: -47.44M (-463.8%)
|
-34.84M
est: -16.02M (-117.5%)
|
-9.84M
est.
|
-8.79M
est.
|
-8.38M
est.
|
-8.52M
-8.52M – -8.52M
-1.6% YoY
|
-49.66M
-49.66M – -49.66M
-482.7% YoY
|
-17.50M
-17.50M – -17.50M
+64.8% YoY
|
-10.77M
-10.77M – -10.77M
+38.4% YoY
|
| SGA |
40.67M
est: 219.74M (-81.5%)
|
40.49M
est: 227.76M (-82.2%)
|
17.22M
est: 99.70M (-82.7%)
|
237.82M
est.
|
250.02M
est.
|
238.55M
est.
|
242.45M
242.45M – 242.45M
+1.6% YoY
|
238.44M
238.44M – 238.44M
-1.7% YoY
|
108.89M
108.89M – 108.89M
-54.3% YoY
|
260.22M
260.22M – 260.22M
+139.0% YoY
|
| EPS |
-2.07
est: -0.09 (-2,280.0%)
|
-3.27
est: -0.53 (-512.2%)
|
-0.30
est: -0.18 (-66.3%)
|
-0.11
est.
|
-0.10
est.
|
-0.09
est.
|
-0.10
-0.10 – -0.10
-1.6% YoY
|
-0.56
-0.56 – -0.56
-482.7% YoY
|
-0.20
-0.20 – -0.20
+64.8% YoY
|
-0.12
-0.12 – -0.12
+38.4% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ali Mahdavi | Director of Capital Markets & Investor Relations | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MJARF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
